Fluconazole shows good penetration into the tissues and body fluids ex
amined and a rapid equilibrium is achieved between the concentrations
in the various compartments. The pharmacokinetics of fluconazole after
intravenous or oral administration are proportional to the dose. This
finding, together with the slow elimination of the triazole (t(1/2) 3
0 h), makes it easier to forecast the therapeutically effective dosage
. Measurements of fluconazole concentrations in blood can be used to p
redict levels in some tissues (lung, brain, gynaecological samples), b
ody fluids (sputum, saliva, vaginal secretions) or exudates. Concentra
tions in cerebrospinal fluid and vitreous humour of the eye reach appr
oximately 80% of the levels found in blood. A very high proportion of
fluconazole is excreted unchanged in the urine, where concentrations o
f the drug are 10-20-fold higher than in blood. Whilst this pharmacoki
netic profile is valuable in the treatment of fungal infections of the
urinary tract, it also means that the dosage may need to be decreased
in patients with renal impairment. The susceptibility of fungi to flu
conazole in vitro and in vivo correlates well with the concentrations
of the drug measured in various compartments of the body.